Clinical trials: Plaque Psoriasis
Psoriasis
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT02786732)
- Testing
- 210mg Brodalumab, 140mg Brodalumab, Ustekinumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MedDerm Associates
Psoriasis
Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis
GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma) that is under development for topical treatment of plaque type psoriasis suitable for topical…
- Trial name
- NCT02548052
- Testing
- GSK2981278 0.03%, GSK2981278 0.1%, GSK2981278 0.8%
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Psoriasis
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- X-PLORE (NCT01483599)
- Testing
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg)
- Where
- 40 sites in United States, Belgium and 3 more
- Volunteers
- 293 people
- Sponsor
- Janssen Inc.
Chronic Plaque Psoriasis
Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
Ultra-violet light B (UVB) therapy has been used by dermatologists to treat psoriasis for decades. Only a few studies have begun to dissect the mechanism of how NB-UVB therapy causes lesion resolution.
- Trial name
- NCT00844363
- Testing
- NB-UVB
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rockefeller University
Plaque Psoriasis
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)
- Trial name
- INDUS-3 (NCT04855721)
- Testing
- AUR101
- Where
- 25 sites in United States
- Volunteers
- 141 people
- Sponsor
- Aurigene Discovery Technologies Limited
Psoriasis
A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test
To investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations of AN2728 in patients with psoriasis vulgaris
- Trial name
- NCT00762658
- Testing
- AN2728 Ointment, 5%, AN2728 Ointment, 2%, AN2728 Ointment, 0.5%
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Pfizer
Psoriasis
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
- Trial name
- NCT00763555
- Testing
- CD 2027, Calcitriol Vehicle
- Where
- 6 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients
Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality.
- Trial name
- NCT06370156
- Testing
- Adalimumab
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Psoriasis
A Phase 3 Clinical Study of KHK4827
This study is designed to evaluate safety and efficacy of long-term exposure of KHK4827 in subjects with moderate to severe plaque psoriasis who have completed the preceding Study 4827-002.
- Trial name
- NCT01782924
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 145 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Psoriasis Vulgaris
Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation
The human body responds to inflammation, such as psoriatic skin lesions, by activating the cholinergic anti-inflammatory pathway. In patients with plaque psoriasis, this pathway is not sufficient to clear the skin lesions.
- Trial name
- NCT05243303
- Testing
- Active taVNS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Burrell College of Health Sciences
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept
This study will provide data on additional therapeutic benefits in administering Adalimumab in patients with plaque psoriasis that showed an unsatisfactory response after at least 3 months of treatment with etanercept.
- Trial name
- NCT00927069
- Testing
- Adalimumab every other week, Adalimumab Every Week
- Where
- 12 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Innovaderm Research Inc.
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
- Trial name
- ICONIC-TOTAL (NCT06095102)
- Testing
- JNJ-77242113
- Where
- 90 sites in United States, Argentina and 9 more
- Volunteers
- 311 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765
To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.
- Trial name
- NCT00205465
- Testing
- VX-765
- Volunteers
- 64 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Psoriasis
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group.
- Trial name
- NCT07724366
- Testing
- TQH3906 capsules, Deucravacitinib tablets 6 mg
- Where
- 45 sites in China
- Volunteers
- 400 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01871402
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 10 sites in United States
- Volunteers
- 221 people
- Sponsor
- Therapeutics, Inc.
Psoriasis, Plaque Psoriasis
Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study
Psoriasis is a chronic inflammatory disease with a multi-factorial etiology which affects the epidermis and dermis. It affects around 1-3% of the general population and its most frequent form is plaque psoriasis (around 80-90% of…
- Conditions
- Psoriasis, Plaque Psoriasis, Periodontal Diseases, Periodontitis
- Trial name
- NCT04722094
- Testing
- Full periodontal chart, Saliva sampling
- Where
- Italy
- Volunteers
- 147 people
- Sponsor
- University of Siena